These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38653622)
41. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY; Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948 [TBL] [Abstract][Full Text] [Related]
42. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428 [TBL] [Abstract][Full Text] [Related]
43. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162 [TBL] [Abstract][Full Text] [Related]
44. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303 [TBL] [Abstract][Full Text] [Related]
45. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer. Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737 [TBL] [Abstract][Full Text] [Related]
46. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. Williams SB; Howard LE; Foster ML; Klaassen Z; Sieluk J; De Hoedt AM; Freedland SJ JAMA Netw Open; 2021 Mar; 4(3):e213800. PubMed ID: 33787908 [TBL] [Abstract][Full Text] [Related]
47. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843 [TBL] [Abstract][Full Text] [Related]
48. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187 [TBL] [Abstract][Full Text] [Related]
49. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Pareek T; Parmar K; Sharma AP; Kumar S Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025 [TBL] [Abstract][Full Text] [Related]
50. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346 [TBL] [Abstract][Full Text] [Related]
51. Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients. Conroy S; Pang K; Jubber I; Hussain SA; Rosario DJ; Cumberbatch MG; Catto JWF; Noon AP BJUI Compass; 2023 May; 4(3):314-321. PubMed ID: 37025474 [TBL] [Abstract][Full Text] [Related]
52. A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Kulkarni GS; Lilge L; Nesbitt M; Dumoulin-White RJ; Mandel A; Jewett MAS Eur Urol Open Sci; 2022 Jul; 41():105-111. PubMed ID: 35813250 [TBL] [Abstract][Full Text] [Related]
54. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment. Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128 [TBL] [Abstract][Full Text] [Related]
55. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial. Achard V; Fournier B; D'Haese D; Krzystyniak J; Tombal B; Roupret M; Sargos P; Dirix P Eur Urol Oncol; 2024 Oct; 7(5):982-985. PubMed ID: 38556413 [TBL] [Abstract][Full Text] [Related]
56. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408 [TBL] [Abstract][Full Text] [Related]
57. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. Chen S; Zhang N; Shao J; Wang X Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363 [TBL] [Abstract][Full Text] [Related]
59. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis. Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493 [TBL] [Abstract][Full Text] [Related]
60. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA; Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]